These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6253098)

  • 1. Clinical experience with misonidazole: high dose fractions versus daily low doses.
    Kogelnik HD
    Cancer Clin Trials; 1980; 3(2):179-86. PubMed ID: 6253098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical experience with daily doses of misonidazole (author's transl)].
    Kogelnik HD; Reinartz G; Szepesi T; Seitz W; Wurst F; Mamoli B; Wessely P; Stark H
    Strahlentherapie; 1980 Nov; 156(11):758-64. PubMed ID: 7434385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further clinical experiences of a phase I study with the hypoxic cell radiosensitizer misonidazole.
    Kogelnik HD; Meyer JH; Jentzsch K; Szepesi T; Kärcher KH; Maida E; Mamoli B; Wessely P; Zaunbauer F
    Br J Cancer Suppl; 1978 Jun; 3():281-5. PubMed ID: 209810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Misonidazole in the preoperative and radical radiotherapy of bladder cancer.
    Awwad HK; El Merzabani MM; El Badawy S; Ezzat S; Akoush H; Abd El Moneim H; Saiid A; Soliman O; Khafagy M; Burgers MV
    Cancer Clin Trials; 1980; 3(3):275-80. PubMed ID: 7438324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Misonidazole in the clinic at Mount Vernon.
    Dische S
    Cancer Clin Trials; 1980; 3(2):175-8. PubMed ID: 7000388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials.
    Dische S; Saunders MI; Flockhart IR
    Br J Cancer Suppl; 1978 Jun; 3():318-21. PubMed ID: 209811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical evaluation of hypoxic cell sensitizer (Misonidazole)].
    Asakawa H; Watarai J; Hoshino T
    Gan To Kagaku Ryoho; 1984 Jun; 11(6):1225-30. PubMed ID: 6732250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final report on the United States Phase I Clinical Trial of the hypoxic cell radiosensitizer, misonidazole (Ro-07-0582; NSC #261037).
    Phillips TL; Wasserman TH; Johnson RJ; Levin VA; VanRaalte G
    Cancer; 1981 Oct; 48(8):1697-704. PubMed ID: 6269723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Misonidazole peripheral neuropathy: its relationship to plasma concentration and other drugs.
    Walker MD; Strike TA
    Cancer Clin Trials; 1980; 3(2):105-9. PubMed ID: 6253094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New side effect of the hypoxic cell sensitizer, misonidazole.
    Partington J; Koziol D; Chapman D; Rabin H; Urtasun RC
    Cancer Treat Rep; 1979 Jan; 63(1):123-5. PubMed ID: 217536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical experiences with the radiation-sensitizing agent misonidazole].
    Kogelnik HD; Szepesi T; Kärcher KH; Seitz W
    Strahlentherapie Sonderb; 1978; 75():115-9. PubMed ID: 162327
    [No Abstract]   [Full Text] [Related]  

  • 12. Plasma concentrations of misonidazole.
    Notter G; Rylander U; Turesson I
    Strahlentherapie; 1980; 156(10):714-8. PubMed ID: 7434379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum.
    Saunders ME; Dische S; Anderson P; Flockhart IR
    Br J Cancer Suppl; 1978 Jun; 3():268-70. PubMed ID: 209808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Misonidazole in fractionated radiotherapy: are many small fractions best?
    Denekamp J; McNally NJ; Fowler JF; Joiner MC
    Br J Radiol; 1980 Oct; 53(634):981-90. PubMed ID: 7426922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral neuropathy related to misonidazole: incidence and pathology.
    Urtasun RC; Chapman JD; Feldstein ML; Band RP; Rabin HR; Wilson AF; Marynowski B; Starreveld E; Shnitka T
    Br J Cancer Suppl; 1978 Jun; 3():271-5. PubMed ID: 209809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Postoperative radiotherapy of astrocytomas grade 3 and 4 with the radiosensitizer misonidazole. -End results of a multicentric controlled German study].
    Sack H; Calcanis A; Godehardt E; Weidtman V; Zülch KJ; Ammon J; Bamberg M; Herbst M; Keim H; Kleibel F; Makoski HB; Potthoff PC; Schlegel G; Schnepper E
    Strahlentherapie; 1982 Aug; 158(8):466-9. PubMed ID: 6753245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical trials of hypoxic cell sensitizer misonidazole].
    Onoyama Y
    Gan No Rinsho; 1983 May; 29(6):718-25. PubMed ID: 6348345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of intravenous L-phenylalanine mustard plus the sensitizer misonidazole.
    Coleman CN; Friedman MK; Jacobs C; Halsey J; Ignoffo R; Leibel S; Hirst VK; Gribble M; Carter SK; Phillips TL
    Cancer Res; 1983 Oct; 43(10):5022-5. PubMed ID: 6883348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Misonidazole-a drug for trial in radiotherapy and oncology.
    Dische S; Saunders MI; Flockhart IR; Lee ME; Anderson P
    Int J Radiat Oncol Biol Phys; 1979 Jun; 5(6):851-60. PubMed ID: 227822
    [No Abstract]   [Full Text] [Related]  

  • 20. The effects of misonidazole during continuous low dose rate irradiation.
    Fu KK; Hurst S; Begg AC; Brown JM
    Cancer Clin Trials; 1980; 3(3):257-65. PubMed ID: 7438323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.